Haw ParHAWPF 95 EBITDA Margin % is 125.82% as of Dec. 2025, which is 42% above its 10-year median of 88.80. GuruFocus rates HAWPF with a GF Score™ of 95/100 and a GF Value™ of $8.79. The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, Haw Par ranks better than 98.64% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Haw Par's EBITDA for the
six
months ended in Dec. 2025 was $101.0 Mil. Haw Par's Revenue for the
six
months ended in Dec. 2025 was $80.3 Mil. Therefore, Haw Par's EBITDA margin for the quarter that ended in Dec. 2025 was 125.82%.
Haw Par (OTCPK:HAWPF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Haw Par EBITDA Margin % Related Terms
Haw Par EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Haw Par's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAWPF vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Haw Par's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haw Par EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haw Par's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Haw Par's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haw Par (HAWPF) has a EBITDA Margin % of 125.82% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Haw Par and its competitors. This is 42% above median its historical median of 88.80. Over the past decade, Haw Par's EBITDA Margin % has ranged from 64.70 to 125.90. According to the industry distribution chart, Haw Par ranks #13 out of 955 companies in the Drug Manufacturers industry, placing it in the top 1.4%.
Is Haw Par's EBITDA Margin % too high?
Haw Par's current EBITDA Margin % of 125.82% is 42% above median its 10-year median of 88.80. Over the past 10 years, this metric has ranged from a low of 64.70 to a high of 125.90. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Haw Par's value of 125.82% is 915.5% above this industry median. Based on the distribution chart, Haw Par ranks #13 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Haw Par has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Haw Par's EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Haw Par ranks #13 out of 955 companies for EBITDA Margin %. This places Haw Par in the top 1% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.39. Haw Par's value of 125.82% is 915.5% above this benchmark. Historically, Haw Par's own EBITDA Margin % has ranged from 64.70 to 125.90 over the past decade. While the company's 10-year median is 88.80 vs. the industry median of 12.39, Haw Par has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haw Par's current EBITDA Margin % of 125.82% is 915.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Haw Par and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haw Par's current EBITDA Margin % is 125.82%, which is 42% above median its own 10-year median of 88.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haw Par stock overvalued right now?
Haw Par (HAWPF) has a current EBITDA Margin % of 125.82%. The stock's GF Value™ is $8.79, compared to a current price of $12.00 — trading 36.5% above its estimated fair value. The current EBITDA Margin % is 125.82%, which is 42% above median its 10-year median of 88.80 and 915.5% above the Drug Manufacturers industry median of 12.39. Haw Par's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Haw Par (HAWPF), the current EBITDA Margin % is 125.82% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haw Par (HAWPF) Overvalued in 2026?
Based on GuruFocus' analysis, Haw Par stock appears to be overvalued.
The current stock price of $12.00 is trading 36.5% above its estimated GF Value™ of $8.79.
Key valuation signals for HAWPF:
EBITDA Margin %: 125.82% (42% above median its 10-year median of 88.80)
GF Value™: $8.79 vs. price of $12.00 (36.5% above fair value)
Industry Position: 915.5% above the Drug Manufacturers median (#13 of 955)
No single metric tells the full story. See the HAWPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, Property segment, and Leisure segment. The company generates the majority of its revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates key revenue from the other ASEAN and other Asian countries.
95GF Score
Get the complete analysis for HAWPF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAWPF has been successfully added to your 
